SBUX has had a remarkable week. The stock is up 8% in five sessions to $104.94. That gap between the stock's momentum and the street's lingering caution is the tension worth watching.
The post-earnings move tells the story. After SBUX reported Q2 results on April 28, the stock jumped 7.8% the next day and held those gains across the full week — a five-day move of 7.2%. The result was good enough to shake out some bears. Short interest has drifted lower over the past month, down about 2.9%, and currently runs at 3.9% of the free float. That's a modest short book for a $120 billion company. Borrow remains cheap at 0.43% annualised — essentially frictionless. Availability is wide, meaning the lending market isn't under any pressure. The ORTEX short score of 42 sits in a neutral zone, and has been drifting higher only slightly over the past two weeks, from 39.4 on April 22 to 42.2 now. Shorts are rebuilding incrementally, not aggressively.
Options positioning tells a more cautious story. The put/call ratio has jumped to 0.91 — 2.5 standard deviations above its 20-day average of 0.82. That's close to its 52-week high of 0.91 reached on April 30. When a stock rallies 8% in a week and options traders are buying this much protection at the same time, someone at the table is nervous. The signal isn't panic, but it is a deliberate hedge against the stock failing to hold its gains into Q3 results, now pencilled in for July 28.
Analysts lifted targets across the board after the print, but the ratings picture remains divided. The bulls — Stifel (raised to $117 this week), Baird and Wells Fargo (both at $115), and Evercore ISI ($115) — see the Brian Niccol turnaround gaining real traction, with accelerating same-store sales growth and improving cost discipline as the core thesis. The bears haven't moved. BNP Paribas kept its Underperform with a $87 target. Guggenheim, Citi and DA Davidson all lifted their targets marginally but stayed at Neutral, each flagging that the stock already reflects much of the good news. The consensus mean target of $105.62 is essentially in line with the current price, which frames the setup clearly: the Street thinks SBUX is fairly valued right here, not cheap. The P/E of 40x and EV/EBITDA of 24x are not demanding multiples for a recovery story, but they do leave little margin for another stumble. On the positive side, EPS momentum ranks in the 89th percentile on a 30-day basis — analysts are still revising estimates higher, which keeps the growth story credible.
The institutional ownership picture reinforces the stability narrative. Capital Research and Management holds 16.2% of shares outstanding and added nearly five million shares in the quarter to March. Vanguard and BlackRock together account for another 17%. T. Rowe Price added close to eight million shares in the same period — a notably large move for a fundamental active manager. These are not momentum flows. They look like conviction positions building quietly into a turnaround trade, with low urgency and long time horizons. Against that, insiders have been consistent net sellers throughout the year — EVP Sara Kelly sold $210,000 worth on April 29, the same day earnings dropped, and the CFO sold in March. The net insider activity over 90 days is a negligibly small positive, dominated by scheduled small transactions rather than any signal of alarm or enthusiasm.
The next print on July 28 will determine whether the 8% post-earnings bounce was the beginning of a sustained re-rating or a relief rally in a recovery that still has a great deal to prove. With the stock now essentially at the analyst consensus target and options traders near their most defensive reading of the past year, the space for a repeat of this week's move is narrower than it looks.
See the live data behind this article on ORTEX.
Open SBUX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
